NVO’s Ryzodeg Approved in Japan – Analyst Blog
Denmark based Novo Nordisk (NVO) recently announced that it has received approval in Japan for its diabetes treatment, Ryzodeg (insulin degludec/insulin aspart). Ryzodeg was submitted for regulatory approval to the Japanese Ministry of Health, Labour and Welfare in March 2012. Ryzodeg is a soluble formulation of Tresiba (insulin degludec) and NovoRapid (insulin aspart [...]
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here